AU2003291614A1 - Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis - Google Patents

Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis

Info

Publication number
AU2003291614A1
AU2003291614A1 AU2003291614A AU2003291614A AU2003291614A1 AU 2003291614 A1 AU2003291614 A1 AU 2003291614A1 AU 2003291614 A AU2003291614 A AU 2003291614A AU 2003291614 A AU2003291614 A AU 2003291614A AU 2003291614 A1 AU2003291614 A1 AU 2003291614A1
Authority
AU
Australia
Prior art keywords
rapidly
identification
bacillus anthracis
lytic enzyme
specifically detect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003291614A
Other languages
English (en)
Other versions
AU2003291614A8 (en
Inventor
Vincent A. Fischetti
Lawrence Loomis
Daniel Nelson
Raymond Schuch
David Trudil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
New Horizons Diagnostics Corp
Original Assignee
New Horizons Diagnostics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Horizons Diagnostics Corp filed Critical New Horizons Diagnostics Corp
Publication of AU2003291614A8 publication Critical patent/AU2003291614A8/xx
Publication of AU2003291614A1 publication Critical patent/AU2003291614A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/32—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
AU2003291614A 2002-05-17 2003-05-19 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis Abandoned AU2003291614A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38087502P 2002-05-17 2002-05-17
US60/380,875 2002-05-17
PCT/US2003/015719 WO2004027020A2 (en) 2002-05-17 2003-05-19 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis

Publications (2)

Publication Number Publication Date
AU2003291614A8 AU2003291614A8 (en) 2004-04-08
AU2003291614A1 true AU2003291614A1 (en) 2004-04-08

Family

ID=32030583

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291614A Abandoned AU2003291614A1 (en) 2002-05-17 2003-05-19 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis

Country Status (6)

Country Link
US (2) US7402309B2 (https=)
EP (1) EP1501925A4 (https=)
JP (1) JP2006513149A (https=)
AU (1) AU2003291614A1 (https=)
CA (1) CA2486280A1 (https=)
WO (1) WO2004027020A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
RU2296576C2 (ru) * 2005-05-18 2007-04-10 Институт биохимии и физиологии микроорганизмов им. Г.К. Скрябина РАН СРЕДСТВО, ОБЛАДАЮЩЕЕ БАКТЕРИЦИДНЫМ ДЕЙСТВИЕМ В ОТНОШЕНИИ ВЕГЕТАТИВНЫХ И СПОРОВЫХ КЛЕТОК Bacillus anthracis, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СИБИРСКОЙ ЯЗВЫ
US8389469B2 (en) * 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
EP2360248A1 (en) * 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
CN100395341C (zh) * 2006-03-09 2008-06-18 中国人民解放军军事医学科学院生物工程研究所 一种表达炭疽杆菌γ噬菌体裂解酶的方法及其专用基因
DE102006061002A1 (de) * 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
US20110059514A1 (en) * 2007-01-09 2011-03-10 David Alexander Schofield Yeast Biocatalysts for Degradation of Biowarfare Agents
CN101003569B (zh) * 2007-01-19 2010-06-23 中国人民解放军军事医学科学院生物工程研究所 炭疽杆菌γ噬菌体裂解酶抗原表位及其突变体与应用
WO2009045581A2 (en) * 2007-06-15 2009-04-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Bacteriophage with enhanced lytic activity
EP2441834A1 (en) 2007-10-01 2012-04-18 Guild Associates, Inc. Differentially Fluorescent Yeast Biosensors for the Detection and Biodegration of Chemical Agents
CA2711841A1 (en) 2008-01-10 2009-09-03 Trustees Of Boston University Engineered bacteriophages as adjuvants for antimicrobial agents and compositions and methods of use thereof
US9157097B2 (en) * 2008-09-25 2015-10-13 Proteovec Holding, L.L.C. Vectors for production of growth hormone
WO2010036979A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of interferon
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
CA2744909A1 (en) * 2008-11-28 2010-06-03 Warren H. Finlay Bacteriophage compositions for treatment of bacterial infections
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors
DK2699253T3 (en) 2011-04-21 2018-07-16 Univ Rockefeller STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES
US9279118B2 (en) 2011-10-05 2016-03-08 The Rockefeller University Dimeric bacteriophage lysins
KR101339908B1 (ko) 2011-11-11 2013-12-10 가천대학교 산학협력단 바실러스 세레우스에 대해 생육 억제능을 나타내는 신규의 박테리오파지
BR112014027818B1 (pt) 2012-05-09 2023-03-28 Contrafect Corporation Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
KR101765393B1 (ko) 2015-11-05 2017-08-07 국방과학연구소 탄저균 특이 용균 단백질 b4의 제조 방법 및 탄저균에 의해 유발되는 질환의 치료 방법
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
EP3454888B1 (en) 2016-05-12 2021-02-24 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
CN110868856A (zh) 2017-07-12 2020-03-06 埃科莱布美国股份有限公司 在工业工艺中快速检测细菌孢子的方法
US11421260B2 (en) 2017-07-12 2022-08-23 Ecolab Usa Inc. Rapid approach for detection of bacterial spores
KR102146555B1 (ko) * 2018-11-27 2020-08-20 국방과학연구소 탄저균 특이적 항균능을 갖는 약학적 조성물 및 이의 제조방법
WO2021092362A1 (en) 2019-11-07 2021-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127215A (en) * 1872-05-28 Improvement in chemical compounds for destroying nicotine in tobacco
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
US20020127215A1 (en) 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation

Also Published As

Publication number Publication date
US20050004030A1 (en) 2005-01-06
AU2003291614A8 (en) 2004-04-08
CA2486280A1 (en) 2004-04-01
JP2006513149A (ja) 2006-04-20
WO2004027020A3 (en) 2004-12-02
US20120164124A1 (en) 2012-06-28
EP1501925A4 (en) 2006-10-25
WO2004027020A2 (en) 2004-04-01
WO2004027020A9 (en) 2004-05-21
US8580553B2 (en) 2013-11-12
EP1501925A2 (en) 2005-02-02
US7402309B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
AU2003291614A1 (en) Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
AU2003221786A1 (en) Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
AU4180900A (en) Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
AU2002237816A1 (en) Point-of-sale activation and subsequent registration of products
AU2001288762A1 (en) Detection and characterization of microorganisms
AU2002357714A1 (en) Sensors and methods of detection for proteinase enzymes
AU2003261319A1 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
EP1575505A3 (en) Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
AU2003278776A1 (en) Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
AU2003301903A1 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2002366501A1 (en) Method of detection and enumeration of bacteria
AU2002341927A1 (en) Detection and identification of enteric bacteria
AU2002223313A1 (en) Protease inhibitors and their pharmaceutical uses
AU2001263402A1 (en) Methods for monitoring production of gene products and uses thereof
AU2003240505A1 (en) Bacteriophage and enzymes lytic to salmonellae
AU2003257470A1 (en) Detection of microorganisms
AU2001250193A1 (en) Novel pyridones and their use as modulators of serine hydrolase enzymes
AU2003300800A1 (en) Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
AU2003299872A1 (en) Vmp-like sequences of pathogenic borrelia species and strains
AU2003277878A1 (en) Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
AU2003302326A1 (en) Rapid detection of microorganisms
AU2001264245A1 (en) Novel enzyme gene and its expression product
AU6424501A (en) Novel enzyme gene and its expression product
AU2002256523A1 (en) Detection of gd2 synthase mrna and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 19, PAGE(S) 5497 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME NEW HORIZONS DIAGNOSTICS CORPORATION, APPLICATION NO. 2003291614, UNDER INID (71) CORRECT THE NAME TO READ NEW HORIZONS DIAGNOSTICS CORPORATION; THE ROCKEFELLER UNIVERSITY